Flexion Therapeutics (FLXN) Cut to “Strong Sell” at BidaskClub

Share on StockTwits

BidaskClub lowered shares of Flexion Therapeutics (NASDAQ:FLXN) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning, BidAskClub reports.

FLXN has been the subject of a number of other research reports. Wells Fargo & Co reissued a buy rating on shares of Flexion Therapeutics in a report on Wednesday, April 10th. Northland Securities reissued a buy rating and issued a $20.00 price objective on shares of Flexion Therapeutics in a report on Friday, March 1st. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Wednesday, February 13th. ValuEngine lowered shares of Flexion Therapeutics from a buy rating to a hold rating in a report on Friday, December 21st. Finally, BMO Capital Markets dropped their price objective on shares of Flexion Therapeutics from $36.00 to $34.00 and set an outperform rating for the company in a report on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $22.64.

Flexion Therapeutics stock opened at $10.63 on Friday. Flexion Therapeutics has a 52-week low of $9.90 and a 52-week high of $29.10. The firm has a market cap of $395.86 million, a PE ratio of -2.37 and a beta of 1.68. The company has a quick ratio of 7.58, a current ratio of 7.78 and a debt-to-equity ratio of 1.35.

In other news, insider Michael D. Clayman acquired 4,046 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average price of $12.36 per share, with a total value of $50,008.56. Following the completion of the acquisition, the insider now owns 70,856 shares of the company’s stock, valued at approximately $875,780.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.59% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of FLXN. Point72 Asset Management L.P. acquired a new position in Flexion Therapeutics in the third quarter valued at about $23,768,000. Capital International Investors acquired a new position in Flexion Therapeutics in the third quarter valued at about $12,162,000. Selz Capital LLC acquired a new position in Flexion Therapeutics in the first quarter valued at about $3,619,000. D. E. Shaw & Co. Inc. lifted its position in Flexion Therapeutics by 516.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 250,402 shares of the specialty pharmaceutical company’s stock valued at $2,835,000 after buying an additional 209,809 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in Flexion Therapeutics in the fourth quarter valued at about $849,000. 94.73% of the stock is currently owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

See Also: Closed-End Mutual Funds

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tenaris SA  Expected to Announce Earnings of $0.35 Per Share
Tenaris SA Expected to Announce Earnings of $0.35 Per Share
Helleniccoin Price Down 11.7% This Week
Helleniccoin Price Down 11.7% This Week
Ultrapar Participacoes  Share Price Crosses Above 50-Day Moving Average of $5.31
Ultrapar Participacoes Share Price Crosses Above 50-Day Moving Average of $5.31
Scorum Coins  Price Up 97.1% This Week
Scorum Coins Price Up 97.1% This Week
Cellectis  Raised to Buy at Zacks Investment Research
Cellectis Raised to Buy at Zacks Investment Research
ZCore   Trading 5.7% Lower  Over Last Week
ZCore Trading 5.7% Lower Over Last Week


 
© 2006-2019 Zolmax.